definiens: means ( i ) the Company ’s novel approach to discovering, researching, developing, manufacturing andcommercializing bi - specific biologic reagents that combine an aﬃnity - enhanced T cell receptor - based targeting system with an anti - CD3 eﬀector functionto activate a T cell response to eradicate disease causing cells ; and ( ii ) any and all algorithms, code, data, documentation, designs, know how, methods, processes, programs, software, target antigens, test results or other technology that is owned or controlled by the Company or any of its Aﬃliates andthat are necessary for the discovery, research, manufacture, development, commercialization or operation of Development Products . For clarity, thePlatform Technology shall include any technologies, libraries, analytical techniques, techniques for the engineering of cell lines ( but not necessarily theengineered cell lines themselves ) materials and know - how that are generated by and on behalf of the Company before or after the Eﬀective Date andwhich are owned, controlled or licensed in ( to the extent sublicensable ) by the Company or its Affiliates